Clinical trials: Urinary Frequency/Urgency
Urge Incontinence
Effectiveness of eCoin at Sensory and Subsensory Amplitudes
The goal of this prospective, multi-center, double-blinded randomized controlled is to learn about effectiveness and QOL with eCoin at two different amplitude settings in subjects with urge urinary incontincence (UUI).
- Trial name
- ESSENCE (NCT05882318)
- Testing
- eCoin Peripheral Neurostimulator System
- Where
- 7 sites in United States
- Volunteers
- 38 people
- Sponsor
- Valencia Technologies Corporation
Pelvic Pain, Interstitial Cystitis
Study of U101 for Bladder Pain and/or Urgency
The purpose of this study is to determine whether intravesical U101 (alkalinized lidocaine-heparin) treatment reduces the symptoms of pelvic pain and/or urgency of bladder origin.
- Conditions
- Pelvic Pain, Interstitial Cystitis, Bladder Diseases
- Trial name
- NCT00256542
- Testing
- Alkalinized Lidocaine-Heparin
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Urigen
Overactive Bladder
An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
The goal of this study is to investigate the safety and effectiveness of a new implanted device designed to treat Urinary Urgency-Frequency Syndrome.
- Trial name
- NCT00131573
- Testing
- bion
- Where
- 11 sites in United States
- Volunteers
- 118 people
- Sponsor
- Boston Scientific Corporation
Overactive Bladder
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).
- Trial name
- NCT00928070
- Testing
- Fesoterodine
- Where
- 125 sites in United States
- Volunteers
- 566 people
- Sponsor
- Pfizer
Urinary Retention, Urinary Urge Incontinence
Axonics SacRal NeuromodulaTIon System RegisTRY Study
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).
- Conditions
- Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
- Trial name
- ARTISTRY (NCT05064384)
- Where
- 27 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Axonics, Inc.
Overactive Bladder
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.
- Trial name
- NCT00911937
- Testing
- Fesoterodine
- Where
- 112 sites in United States
- Volunteers
- 963 people
- Sponsor
- Pfizer
Urgency Urinary Incontinence
eCoin Tibial Nerve Stimulation for OAB
The study is a single arm, prospective study of the safety and effectiveness of the Valencia Technologies eCoin System to stimulate the tibial nerve for the treatment of patients with refractory urgency urinary incontinence.
- Trial name
- NCT03029624
- Testing
- eCoin
- Where
- 7 sites in United States, New Zealand
- Volunteers
- 46 people
- Sponsor
- Valencia Technologies Corporation
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients
This is a two-part study in which Part A will assess the effects of GW679769 after 1 dose on the function of the nerves that supply the bladder. The technique for measuring the nerves function is called Neurometry.
- Trial name
- NCT00332319
- Testing
- GW679769
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Urge Incontinence
Protect Chronic Tibial Nerve Stimulator (CTNS) System
30 patient Study. All patients implanted with StimGuard Protect System. Patient followed out to 90 days.
- Trial name
- NCT02781636
- Testing
- Device: StimGuard Protect System
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Uro Medical Corporation
Benign Prostatic Hyperplasia
A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)
Benign prostatic hyperplasia (BPH), also known as an enlarged prostate, happens more often in men as they age. This condition causes a sudden need to pass urine, which is hard to control.
- Trial name
- NCT07619105
- Testing
- Vesomni
- Volunteers
- 600 people
- Sponsor
- Astellas Pharma Korea, Inc.
Overactive Bladder (OAB)
Detrol LA In Men With Overactive Bladder.
An interventional active/placebo double blinded parallel randomized controlled study in which at 12 weeks of treatment, the primary endpoint of patient perception of bladder condition is measured along with associated safety and…
- Trial name
- NCT00282932
- Testing
- Detrol LA
- Where
- 81 sites in United States, Canada and 13 more
- Volunteers
- 600 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder
Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)
The aim of the study is to determine how well the drug BAY1817080 works in OAB patients with urgency urinary incontinence (UUI), defined as involuntary leakage of urine, accompanied or immediately preceded by a sudden compelling…
- Trial name
- OVADER (NCT04545580)
- Testing
- BAY1817080
- Where
- 28 sites in Australia, Austria and 7 more
- Volunteers
- 99 people
- Sponsor
- Bayer
Overactive Bladder
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
The purpose of this study is to determine the optimal dose of botulinum toxin type A injected in the detrusor muscle to improve urinary symptoms, urodynamic parameters and quality of life of continent women suffering from…
- Trial name
- NCT00578097
- Testing
- Botulinum toxin type A
- Where
- 34 sites in Belgium, Czechia and 6 more
- Volunteers
- 81 people
- Sponsor
- Ipsen
Urinary Incontinence
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge…
- Trial name
- NCT00147654
- Testing
- Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
- Where
- 95 sites in United States
- Volunteers
- 830 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Urinary Incontinence, Urge
Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt
The ARTISAN-SNM study is designed to evaluate the safety and effectiveness of the Axonics Sacral Neuromodulation System as an aid in the treatment of the symptoms of urinary urgency incontinence (UUI) in patients who have failed…
- Trial name
- ARTISAN-SNM (NCT03327948)
- Testing
- Axonics Sacral Neuromodulation System (SNM) System
- Where
- 4 sites in United States, Netherlands and 1 more
- Volunteers
- 129 people
- Sponsor
- Axonics, Inc.
Urinary Bladder, Overactive
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of YM178 against placebo and tolterodine to treat patients with symptoms of over active bladder.
- Trial name
- Blossom (NCT01604928)
- Testing
- YM178, tolterodine
- Where
- 30 sites in Belgium, Czechia and 4 more
- Volunteers
- 260 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Incontinence, Urge
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system.
- Trial name
- PROTECT (NCT02577302)
- Testing
- CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
- Where
- 15 sites in United States
- Volunteers
- 200 people
- Sponsor
- Uro Medical Corporation
Overactive Bladder
Overactive Bladder Innovative Therapy Trial (OrBIT)
The purpose of this study is to compare percutaneous tibial nerve stimulation (PTNS) to drug therapy for the treatment of symptoms of overactive bladder (OAB).
- Trial name
- OrBIT (NCT00448175)
- Testing
- Urgent PC Neuromodulation System, Tolterodine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Uroplasty, Inc
Overactive Bladder, Urinary Urgency Incontinence
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
- Conditions
- Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer
- Trial name
- NCT06511141
- Testing
- Axonics SNM System
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Axonics, Inc.
Urinary Bladder, Overactive
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
This study is to assess the efficacy and safety of YM178 in patients with symptoms of overactive bladder.
- Trial name
- NCT01043666
- Testing
- YM178, tolterodine ER
- Where
- 35 sites in China, India and 2 more
- Volunteers
- 1,126 people
- Sponsor
- Astellas Pharma Inc